TRACON Pharmaceuticals Announces Publication in Blood of Preclinical Data Indicating Activity of TRC105 in Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Dr.
“We have been studying the function of endoglin in hematopoiesis for more than a decade, and the consistent expression of this receptor in the majority of acute leukemias was intriguing. Our hypothesis that endoglin expression was linked to leukemia-forming activity was proven to be true, and it was even more rewarding to witness the robust anti-leukemogenic effect of blocking endoglin signalling with TRC105, even when leukemia had already been established in the mouse,” said Dr. Perlingeiro. “We are thrilled with the potential of our basic research to contribute to the development of a new line of therapy for patients with AML and B-cell ALL.”
“We are pleased to see that this promising research, conducted by Dr. Perlingeiro and her collaborators, has been published in Blood,” said
About Carotuximab (TRC105)
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in one Phase 3 and multiple Phase 2 clinical trials sponsored by TRACON or the
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with
Forward-Looking Statements
Statements made in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding the potential benefits of TRC105 (including its potential to be developed as a treatment for AML and B-cell ALL), TRACON's plans to further develop its product candidates and expectations regarding the initiation, design and timing of future clinical trials by TRACON or third parties. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: risks associated with clinical development; whether TRACON or others will initiate or complete additional preclinical studies or clinical trials; the fact that future preclinical studies and clinical trials may not be successful or otherwise consistent with results from prior studies; potential changes in regulatory requirements in
View online version: www.bloodjournal.org/content/129/18/2526.long?sso-checked=true
Company Contact:Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 clogan@traconpharma.com Investor Contact:Andrew McDonald LifeSci Advisors LLC 646-597-6987 Andrew@lifesciadvisors.com